| Trial ID: | L2086 |
| Source ID: | NCT01842282
|
| Associated Drug: |
Amlexanox
|
| Title: |
Amlexanox for Type 2 Diabetes and Obesity
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01842282/results
|
| Conditions: |
Diabetes Mellitus Type 2|Non Alcoholic Fatty Liver Disease|Obesity
|
| Interventions: |
DRUG: Amlexanox
|
| Outcome Measures: |
Primary: HbA1c, Change in HbA1c from baseline to 12 weeks as shown by mean increase or decrease of HbA1c where decreased values represent better health, 12 weeks|Hepatic Steatosis by MRI, change in hepatic steatosis from baseline to 12 weeks: MRI Liver fat percentage as shown by mean difference, 12 weeks | Secondary: Weight, Change in weight (Kg) from baseline to 12 weeks as shown by mean difference, where lower weights represent healthier outcomes, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Michigan
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
7
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-07-19
|
| Completion Date: |
2014-02-25
|
| Results First Posted: |
2024-01-17
|
| Last Update Posted: |
2024-05-07
|
| Locations: |
University of Michigan, Ann Arbor, Michigan, 48109, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01842282
|
